Covington advised LifeArc on the deal. The deal consists of LifeArc monetization of a portion of its royalties relating to Keytruda® for $1.297 billion (approximately £1…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
